Literature DB >> 2406016

Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections.

B Loridon-Rosa1, P Vielh, H Matsuura, H Clausen, C Cuadrado, P Burtin.   

Abstract

Two types of human fibronectin have been detected by the reactivity of specific monoclonal antibody FDC-6: (a) those present in normal plasma and adult tissues, which do not react with FDC-6 (normal fibronectin or norFN); and (b) those present in fetal tissues and in tumoral cell lines, which do react with FDC-6 (oncofetal fibronectin or onfFN) (H. Matsuura and S. I. Hakomori, Proc. Natl. Acad. Sci. USA, 82: 6517-6521, 1985). We compared the distribution of norFN and onfFN in normal breast tissue (15 samples), breast fibroadenoma (ten samples), and breast adenocarcinoma (80 samples), using an immunofluorescence technique with monoclonal antibody FDC-6. A polyclonal antiserum against human normal fibronectin was used as a control. While norFN was diffusely present in normal gland and in benign and malignant tumors, onfFN was absent in normal gland and in benign tumors. In carcinomas, however, its presence was frequent, as we found it in 60% of cases. Among classical prognosis factors in breast carcinomas, onfFN distribution was significantly correlated with histological grade. Indeed, the presence of FDC-6 labeling was significantly linked with intermediary and high malignancy grades, while its absence was significantly linked with low malignancy grade. onfFN could be considered a marker of the neoplastic state; its immunohistological detection may represent a new prognosis factor in breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406016

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.

Authors:  Mingqian Tan; Xueming Wu; Eun-Kee Jeong; Qianjin Chen; Dennis L Parker; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 3.  A visual-quantitative analysis of fibroblastic stromagenesis in breast cancer progression.

Authors:  Edna Cukierman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

4.  Is oncofetal fibronectin a trophoblast glue for human implantation?

Authors:  R F Feinberg; H J Kliman; C J Lockwood
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

5.  Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging.

Authors:  Mingqian Tan; Xueming Wu; Eun-Kee Jeong; Qianjin Chen; Zheng-Rong Lu
Journal:  Biomacromolecules       Date:  2010-03-08       Impact factor: 6.988

6.  Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner.

Authors:  Roderick M Quiros; Matthildi Valianou; Youngjoo Kwon; Kimberly M Brown; Andrew K Godwin; Edna Cukierman
Journal:  Gynecol Oncol       Date:  2008-05-02       Impact factor: 5.482

7.  Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts.

Authors:  P Pujuguet; A Hammann; M Moutet; J L Samuel; F Martin; M Martin
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

Review 8.  Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.

Authors:  Ivan O Potapenko; Vilde D Haakensen; Torben Lüders; Aslaug Helland; Ida Bukholm; Therese Sørlie; Vessela N Kristensen; Ole C Lingjaerde; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2009-12-11       Impact factor: 6.603

9.  Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.

Authors:  Yajuan Li; Zheng Han; Sarah Roelle; Aidan DeSanto; Rob Sabatelle; Rebecca Schur; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2017-10-25       Impact factor: 4.939

10.  IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Authors:  Petra Richter; Kerstin Junker; Marcus Franz; Angela Berndt; Christiane Geyer; Mieczyslaw Gajda; Hartwig Kosmehl; Alexander Berndt; Heiko Wunderlich
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.